Extensive clinical studies of Helicobacter pylori have shown this bacterium to be an important causative factor of peptic ulcer, particularly in its recurrence. Therefore, numerous therapeutic trials for the eradication of H. pylori have been reported. A recent trend in curative therapy has been so-called triple therapy, using a proton pump inhibitor and two different antimicrobials. 1 Sucralfate, which is a widely used cytoprotective agent for the gastric mucosa, is reported to inhibit several of the activities of H. pylori and to enhance the anti-H. pylori activity of antimicrobial agents. 2±11 Therefore, several studies of sucralfate-based eradication therapy have been reported recently. 12±18 However, the ef®cacy and safety of sucralfate-based therapy are still controversial. 19±20 The present study was designed to evaluate the ef®cacy and safety of sucralfate in combination with amoxycillin and clarithromycin as eradication therapy for H. pylori, in comparison with lansoprazole-based triple therapy. PATIENTS AND METHODS PatientsThis study was designed as a prospective, randomized, multicentre study, and was carried out in accordance SUMMARY Background: Sucralfate has an inhibitory action against Helicobacter pylori and enhances the anti-H. pylori activity of antimicrobials. Aim: To evaluate the ef®cacy and safety of sucralfatebased eradication therapy for H. pylori infection, compared with that based on lansoprazole, in a randomized multicentre study. Subjects and methods: The subjects were 150 H. pyloripositive patients. They were randomly assigned to one of two regimens for 2 weeks: sucralfate 1 g t.d.s., amoxycillin 500 mg t.

No abstract

No abstract

No abstract

No abstract